Because we demonstrated the role of CDK6 in the activation of β-catenin in lenvatinib-resistant HCC cells, we hypothesized that palbociclib converts the immune-suppressive environment to an immune-inflamed environment. The gene discussed is CDK6; the disease is hepatocellular carcinoma.